Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Ziftomenib |
Synonyms | |
Therapy Description |
Ziftomenib is a small molecule inhibitor of MEN1 (menin)-KMT2A (MLL1) complex, which may lead to decreased growth KMT2A (MLL1)-positive tumor cells, and inhibition of tumor growth (PMID: 36151141). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Ziftomenib | KO539|KO 539|KO-539 | MEN1-KMT2A Inhibitor 8 | Ziftomenib is a small molecule inhibitor of MEN1 (menin)-KMT2A (MLL1) complex, which may lead to decreased growth KMT2A (MLL1)-positive tumor cells, and inhibition of tumor growth (PMID: 36151141). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
KMT2A rearrange | acute myeloid leukemia | no benefit | Ziftomenib | Phase I | Actionable | In a Phase Ib trial (KOMET-001), Ziftomenib treatment resulted in an overall response rate of 17% (3/18) and a complete remission or complete remission with partial hematologic recovery rate of 11% (2/18) at the recommended Phase II dose level in acute myeloid leukemia patients harboring KMT2A rearrangements, but enrollment was halted due to increased frequency of differentiation syndrome (PMID: 39362248; NCT04067336). | 39362248 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT04067336 | Phase I | Ziftomenib | First in Human Study of KO-539 in Relapsed or Refractory Acute Myeloid Leukemia | Recruiting | USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | 0 |
NCT05848687 | Phase Ib/II | Bortezomib Dexamethasone Blinatumomab Vorinostat Mercaptopurine Pegaspargase Methotrexate Ziftomenib Mitoxantrone | TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II | Recruiting | USA | CAN | 0 |
NCT06440135 | Phase I | Ziftomenib | Ziftomenib Maintenance Post Allo-HCT | Recruiting | USA | 0 |